@prefix chebi: . @prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix go: . @prefix Protein: . @prefix sfam: . @prefix geneProductOf: . @prefix hasAgent: . @prefix do: . @prefix occursIn: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 hasAgent: sub:_2; a go:0016301 . sub:_2 geneProductOf: sfam:AKT%20Family; a Protein: . sub:_3 occursIn: do:162, species:9606; rdf:object sub:_1; rdf:predicate belv:increases; rdf:subject chebi:9168; a rdf:Statement . sub:assertion rdfs:label "a(SCHEM:Sirolimus) -> kin(p(SFAM:\"AKT Family\"))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "20131211" . sub:_4 prov:value "Although previous studies had shown that the consequence of functional loss of the TSC complex on PI3K was prevented by rapamycin (Harrington et al., 2004), it was not until 2006 that the group of Dr Rosen demonstrated that rapamycin treatment induced AKTactivatio n in cancer patients, a strong drawback for the use of this family of inhibitors as single agent in the clinic (O’Reilly et al., 2006)."; prov:wasQuotedFrom pubmed:18794886 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:18794886; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dct:created "2014-07-03T14:33:25.210+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }